CompletedPhase 3NCT04578496

A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)

Studying Autosomal erythropoietic protoporphyria

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Clinuvel Pharmaceuticals Limited
Principal Investigator: Pilar Bilbao
Clinuvel Pharmaceuticals Limited
Intervention: Afamelanotide(drug)
Enrollment: 16 enrolled
Eligibility: 18-75 years · All sexes
Timeline: 2011 – 2014

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04578496 on ClinicalTrials.gov

Other trials for Autosomal erythropoietic protoporphyria

Additional recruiting or active studies for the same condition.

ENROLLING BY INVITATIONPHASE2, PHASE3NCT05883748
HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP
Disc Medicine, Inc

See all trials for Autosomal erythropoietic protoporphyria →

← Back to all trials